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Abstract
Background: Around 303,000 maternal deaths occur every year; most of these are preventable (World Health
Organization), ICD-10: International classification of diseases and related health problems, 10th revision. Volume 2:
Instruction manual, 2010). Ninety-nine percent of these maternal deaths occur in developing countries. PPH
contributed 35 % (35%) of total maternal. Several interventions being done to reduce the number of maternal
deaths. It has been noted that a simple low cost intervention of providing misoprostol timely could prevent these
deaths.
Objectives: The objectives of this systematic review was to identify barriers/gaps in the implementation of
misoprostol use for prevention of postpartum hemorrhage and management of Post-abortion care services in
developing countries.
Methods: This study was a systematic review of published qualitative and quantitative literature on misoprostol in
developing countries. Documents included were local and international peer reviewed articles and program reports
on misoprostol implementation. PubMed, Google Scholars and Science direct databases were used along with Grey
literature and manual search using terms “implementation gaps”, “misoprostol use”, “postpartum hemorrhage”,
“post-abortion care” and “developing countries”.
Results: Gaps or barriers in misoprostol use identified through systematic review can be categorized into six
broader thematic areas including: inconsistency in supplies and its distribution; inadequate staffing; lack of
knowledge of providers and end users, absence of the registration of drug and fear and apprehensions
related to its use at provider and policy level.
Conclusion: It is concluded that barriers and gaps can be addressed through providing enabling environment
through supportive policies, designing a formal plan for supplies, task shifting strategies and use of guidelines and
protocols for successful implementation.
Keywords: Misoprostol, Post abortion care, Postpartum hemorrhage, Developing countries
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Plain English summary
Maternal death in developing countries is common
across the globe. Post-partum hemorrhage (PPH) is the
major contributor of these deaths. Oxytocin is considered as the first line drug and it is widely used by health
care providers since decades to prevent and manage
PPH but on the basis of emerging body of evidences
World Health Organization (WHO) recommended misoprostol use for similar conditions in settings where
oxytocin is not available and included misoprostol in its
essential medicines list (EML) model in March 2011.
Realizing the importance of misoprostol in averting postpartum hemorrhage and abortion related complications,
misoprostol has been recommended for primary prevention of PPH.
However, many developing countries are facing barriers in proper implementation of misoprostol. This systematic review was aimed to identify barriers or gaps in
the implementation of misoprostol use for prevention of
postpartum hemorrhage and management of Postabortion care services in developing countries; and suggest recommendations for its elimination.
Systematic review of published qualitative and quantitative literature on misoprostol in developing countries
were search based on eligibility criteria using data bases
that include; PubMed, Google Scholars and Science direct along with Grey literature and manual search using
search terms “implementation gaps”, “misoprostol use”,
“postpartum hemorrhage”, “post-abortion care” and “developing countries”. Total 19 studies were included for
analyses purpose.
Based on review findings it is concluded that barriers and gaps can be addressed through providing
enabling environment through supportive policies, designing a formal plan for supplies, task shifting strategies and use of guidelines and protocols for successful
implementation (Additional file 1; Table S1).
Background
Around 303,000 maternal deaths occur every year; most
of these are preventable [1]. Ninety-nine percent of these
maternal deaths occur in developing countries [2, 3];
with Sub-Saharan African and south Asian countries accounts for 66% (201,000) and 21.7% (187,000) respectively of total maternal mortality [1].
The overall Maternal Mortality Ratio (MMR) in developing countries is 239 per 100,000 live births which is
20 times higher than developed regions [1, 3]. SubSaharan African countries have very high MMR of 546/
100,000 live births; whereas South Asian Countries have
MMR of 176/100,000 live births. In Pakistan Maternal
Mortality Ratio (MMR) is 178/100,000 live births which
is still higher than MDGs targets of maternal mortality
reduction [1].
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Five direct causes of maternal mortality are; Postpartum
hemorrhage (PPH), unsafe abortions (or related complications), eclampsia, obstructed labor and sepsis [4]; PPH
contribute 35 % of total maternal deaths in developing
countries and continue to be the leading cause of maternal
mortality [1]. PPH is the predominate cause of maternal
mortality in Africa (34%) and Asia (31%) [5] where most
of the maternal deaths occur. Despite under-reporting because of stigma [6] abortion still is a major contributor of
maternal deaths; in 2013; approximately 15% maternal
deaths occurred globally as a result of abortion related
complications [7].
Oxytocin is considered as the first line drug and it is
widely used by health care providers since decades to
prevent and manage PPH but on the basis of emerging
body of evidences World Health Organization (WHO)
recommended misoprostol use for similar conditions in
settings where oxytocin is not available and include misoprostol in its essential medicines list (EML) model in
March 2011 [5]. As a result, WHO 2012 guidelines for
PPH management recommend the administration of misoprostol by Community Health Workers (CHWs) for
PPH prevention [5]. Misoprostol has been 95% effective
for managing incomplete abortion in poor resource settings [8]. Moreover, the drug is the best acceptable and effective substitute of Manual Vacuum Aspiration (MVA)
for incomplete abortion [9]. Realizing the importance of
misoprostol in averting postpartum hemorrhage and abortion related complications, misoprostol has been recommended for primary prevention of PPH [10].
Despite these recommendations; developing countries
have yet not successfully implemented misoprostol use
to prevent PPH and reduce maternal deaths. This therefore has identified the need to explore barriers or gaps
hindering misoprostol implementation [9].
Pakistan is among low-resource setting countries
where misoprostol could be the drug of preference to reduce deaths from PPH as majority of the deliveries take
place at home assisted by Dai (a local term used for
TBAs) or family member [11].
The objectives of this systematic review were to: identify
barriers or gaps in the implementation of misoprostol use
for prevention of postpartum hemorrhage and management of Post-abortion care services in developing countries;
and suggest recommendations for elimination of barriers or
gaps in implementation of misoprostol to reduce maternal
mortality in developing countries. The below Fig. 1 depicts
the conceptual framework designed by the author specific
to the context of this study to understand the overall approach of this study (Additional file 1; Table S2).

Methods
This study was a systematic review of published Qualitative and Quantitative literature from March, 2012 to
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Fig. 1 Conceptual framework

July, 2016 on implementation of misoprostol in developing
countries. Preferred reporting items for systematic review
and Meta-Analysis (PRISMA) checklist has been used for
this systematic review (Additional file 2). PRIMSA comprised of 27 items checklist (refer Additional file 1; Table
S3 below). The aim of PRISMA statement is to assist author to improve systematic review reporting [12].
Search strategy was developed to identify publications and
project reports that had explored barriers/ gaps in implementation of misoprostol using three data bases concomitantly; that include, Google Scholars, PubMed, and Science
direct using search strategy, “Implementation gaps OR barriers AND misoprostol use AND Postpartum hemorrhage
AND post abortion care AND developing countries”.
Following are the eligibility criteria for including or excluding articles included; Year of publication: March,
2012 till July, 2016 (because in March, 2012; the WHO
guidelines for the prevention and management of PPH
have included a recommendation for the administration
of misoprostol by CHWs for the prevention of PPH) [5].
Focus should be on Human species, Published articles
must be in English language, Gender: female (female related conditions), Developing country context, Drug of
focus: misoprostol, Maternal condition related to Postpartum Hemorrhage (PPH) prevention, Post Abortion
care (PAC) services, Articles/reports (grey literature) included irrespective of the publication status if qualifying
the selection criteria (refer Fig. 2, below).
 Population: Developing countries where the

misoprostol intervention is implemented.

 Intervention: Misoprostol for prevention Post-

Partum Hemorrhage (PPH) and for management of
Post abortion care (PAC)
 Comparison: Since this review is not the clinical
trial, rather a health system research hence there is
no comparison group
 Outcome: the considered outcome could be any one
of the following 1) reduced incidence of PPH 2)
reduced abortion related complications 3) reduced
maternal morbidity4) reduced maternal mortality.
Since outcome assessment is beyond the scope of
this systematic review, therefore the possible
outcomes were not assessed.
A self-designed data extraction form was developed
through an iterative process to recognize all data set that
considered most critical to this review objective. Information gathered from eligible studies comprised of name
of journal, date of review, publication year, study settings, study design, methodology for data collection, targeted audience, variable of interest, implementation
barriers or gaps identified, advantages of misoprostol, either excluded or not, conclusion and recommendations/
policy implications. Lastly, the information extracted
from 20 included studies were documented in extraction
form (Additional file 1; annexure 1.1-1.20).
Methodological assessment of quality of this systematic
review

An AMSTAR checklist was used as a measurement tool
to assess the methodological quality of this systematic
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Fig. 2 Consort diagram for data screening process

review. Principles of AMSTAR tool can be used to demonstrate aspects of systematic review methodology that influence the overall quality of review. An overall score
relating to review quality was calculated. AMSTAR Characterized quality at three level includes high quality (Score
ranges from 8 to 11), medium quality (score ranges from
4 to 7) and low quality (score ranges from 0 to 3) [13].
The methodological assessment of this systematic review
revealed total score of 9 which reflects high quality of systematic review (Additional file 1; Table S4).

Quality assessment of included studies

The Mirza and Jenkins checklist was used for assessing
the quality of each included studies. The quality assessment criteria include 1) Explicit study aims stated 2) justification of sample size given 3) sample representation
of population 4) inclusion and exclusion criteria stated
5) reliability and validity of measured justified 6) response rate and dropout rate specified 7) data adequately
described 8) statistical significance assessed 9) discussion
on generalizability given 10) null finding interpreted
[14]. Out of 19 included studies, only single study gave
complete methodological details as per checklist.
Based on Quality of evidence criteria: score ≤ 5 is low;
score of >5 and ≤7.5 is moderate; and score of ≥7.6 is
high. Out of 19 studies, the 13 studies (n = 13) were categorized as moderate; whereas six studies (n = 6) were
categorized has high quality studies. However only single

study falls under low quality evidence thus excluded
from this systematic review (Additional file 1; Table S5).

Results
As mentioned above, from the list of 20 shortlisted articles for full text review, one study was excluded as it
was not capturing any barrier or gap related to misoprostol. The selected 20 studies were run from preformulated data extraction form that includes; study citation, objectives, study settings, study design and data
collection methods, barriers identified, conclusion, recommendations and limitations of the study.
Below Table 1 depicts the summarize findings contained
study settings and study design from selected studies.
Table 1 Summary of findings
Study Settings

Developing countries that include, Bangladesh,
Afghanistan, Ethiopia, Ghana, Kenya, Uganda,
Northern Nigeria, Tanzania, India, Pakistan
Kosovo, Malawi, Myanmar, Sub-Saharan African
countries (Democratic Republic of Congo, Maban
& Burkina Faso).

Study design

• Qualitative inquiry using In-depth interviews
and FGD’s (n = 7)
• Mixed method design (n = 3)
• Situational analysis (n = 3),
• Cross-sectional study design (n = 2)
• Before and after study design (n = 2).
• Web based survey (n = 1)
• Evaluation approach as study design (n = 1).
• Special communication (n = 1)
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All the studies included in this review were from developing countries. The findings from the included studies
were categorized into six categories. These six categories
were further divided into sub-categories and each finding
is segregated accordingly (refer Table 2 below).
The thematic areas reflected the health system building block framework proposed by WHO in 2007 describing health system in term of six core components
that include Health service delivery, Health workforce,
Health information systems, access to essential medicines, health care financing and health care leadership/
governance [15, 16]. In context to this systematic review
author has slightly modified these health system building
blocks framework by combining the two building blocks
that are health service delivery and access to essential
medicine and adding issues related to community knowledge and perception; since many studies have highlighted
barriers pertaining to this particular thematic area.
1. Barriers or gaps related to Leadership, governance,
Guidelines and Policy related
The majority of studies (12/19) had identified that
leadership, governance and policy related issues are
substantial barriers in successful implementation of
misoprostol in developing countries. More
specifically, lack of registration of misoprostol for the
management of PAC or PPH were highlighted
(n = 3) [9, 11, 17].
Few studies (n = 3) had identified existence of fear and
confusion among implementers, policy makers and
government officials [17–19]. Specifically lack of
awareness about existing policy (n = 2) [9, 20] and lack
of integration of misoprostol in basic health service
Package (n = 2) were important barriers found [21, 22],
moreover it was also explored that there were technical
inconsistencies and ambiguity in guidelines and
protocols at policy level [17, 23].
Under the similar domain two studies have
identified Rudimentary or absent transportation
(related to road infrastructure) and communication
system as barrier [18, 24].
A Cross-sectional study from 37 developing countries using Key informant interviews revealed that
majority of the countries have included Oxytocin in
essential medicine list and have less preference for
misoprostol to prevent PPH [23] also misoprostol
use to prevent PPH at home birth have piloted in
some countries but far fewer have taken the strategy
to scale up [23].
2. Barriers or gaps related to Health service delivery,
and availability and access to essential medicines:
More than half of the studies (n = 10/19) identified
barriers or gaps related to health service delivery and
access to essential medicine. Among these the most
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frequently reported was issues related to
inconsistencies in supplies/ fragmented supply
chain and distribution (n = 8/10) studies, have
reported this similar issue [7, 9, 18, 19, 22–25].
Remaining two studies (n = 2) out of 19 have
identified lack of access to misoprostol as the
barrier for increasing coverage and optimal
utilization [19, 24].
3. Barriers or gaps related to Health Workforce:
Significant number of studies (14/19) have identified
gaps or barriers related to health workforce. The
most repeatedly reported gap/barrier were scarcity
or inadequate staffing of SBA’s, TBA’s, and CHW’s
(n = 6) [9, 18, 21, 24–26] fear and confusion of the
providers (n = 5) [8, 17, 22, 25, 27]. Fear in term of
misuse of drug due to its abortion inducing properties
or administration in event of an undiagnosed twin
(lead to fatal outcome), administration during labor
(causing uterine rupture) and use for unsafe abortion
[17], furthermore same study also mentioned that in
response to advance distribution; fears concerning
intra-partum administration, undiagnosed multiple
gestation, medication sharing and possibility of its use
after expiry were also the added fear that could
jeopardize misoprostol distribution. In addition to this
it was also mentioned in same study that, it is believed
by some the providers that misoprostol will increase
the home based delivery and limit the facility based
delivery and thus deviating away from the strategy to
increase use of facilities for birth [19]. Lack of awareness
of the existence of guidelines and clarity of guidelines
(n = 4) [11, 20, 22, 24] and lack of knowledge and Skills
of providers was also highlighted (n = 3) [7, 25, 28].
4. Barriers related to Community perception, Knowledge
and preference:
Nearly half of the studies (8/19) have identified
barriers or gaps related to community perception,
knowledge and preference. Most common factors in
this domain were; lack of acceptability and negative
attitude due to its abortion inducing properties
(n = 3) [7, 11, 26]; lack of access to misoprostol due
socio-economic, Ethnic and cultural barriers (n = 2)
[22, 27]; lack of community awareness and knowledge
for misoprostol (n = 2) [26, 29]; and inequitable distribution of misoprostol is an equitable intervention that
can reduce disparities in access to it [21].
5. Barriers or gaps related to Health Information System:
Only single study out of 19 studies has identified
barriers or gaps related to health management
information system that include absence of national
reporting system on uterotonics use, along with gaps
in inclusion of key maternal health indicators at
national level impedes and continues to limit
progress. Combining enough data on
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Table 2 Barriers or gaps identified from included articles
(Continued)
S.No Health System Building
Blocks/Thematic Areas

Barriers or gaps related to
Health Workforce (14
studies)

Sub-Themes for identified
gaps or barriers

Number of
studies
identified similar
gap/barriers

Table 2 Barriers or gaps identified from included articles
S.No Health System Building
Blocks/Thematic Areas

Sub-Themes for identified
gaps or barriers

1

Lack of national policies
2
and guidelines for MPAC or
PPH

Lack of Knowledge & Skills
(Technical & non –
technical) of providers

Barriers or gaps related to
Leadership, governance,
Guidelines and Policy
related (12 Studies)

No Registration of
misoprostol Specific for
PAC or PPH

3

Fear and apprehensions
related to its use

3

6

Fear, apprehensions and
doubt related to
misoprostol

5

Misoprostol not included in 1
National list of essential
medicines

Negative or Judgmental
attitude of providers

1

Limited scope of practice
of midwifes

1

Lack of training and
training capacity of
providers

2

scarcity of staff or
inadequate staffing (SBA’s,
TBA’s, CHW’s)

5

6

Issues related to
Community perception,
Knowledge and preference:
(8 Studies)

Barriers or gaps related to
Health information system
(1 Study)

Barriers or gaps related to
cost of medicine (2
Studies)

legal restrictions that only
permits pregnancy
termination to save life of
mother

1

No or Less Preference to
misoprostol

1
2

Lack of communication/
inter-professional
collaboration

2

Lack of integration of
misoprostol with Basic
package of health services/
health care resources

1

Lack of Motivation among
provider

1

Poorly developed
Commodity security
strategies.

3

Rudimentary or absent
Transportation and
communication system.

2

Lack of acceptability and
negative attitude due to
stigma associated due to
its abortion inducing
properties

1

Hindrance from relatives in
taking misoprostol

1

Lack of ability to
implement and monitor
implementation and
current practices.

Lack of community
awareness and knowledge
for misoprostol

2

Lack of trust between
1
clinicians and policy makers
1

Lack of health seeking
behavior

2

Gaps in pre-service medical
and midwifery education
program curriculum.

1

Technical inconsistencies
and ambiguity in
guidelines and protocolsincomplete and out dated.

2

Lack of preference to
Medical Abortion using
misoprostol
Lack of access to
misoprostol due socioeconomic, Ethnic and cultural barriers

2

Lack of communication or
awareness of existing
policy

2

1

Lack of Access to
misoprostol

2

Patients’ lack of trust of
lower-cadre health workers

PAC services not available

1

Disparities in service
utilization between rural
and urban

1

8

Lack of national reporting
on HMIS on use of
uterotonics.

1

Issues related to
inconsistencies in supplies/
fragmented supply chain
and distribution
Lack of Supervision/
Monitoring capacity

1

Gaps in inclusion of
maternal health indicators
in national data

1

Reduced institutional
delivery

1

Paying for medicine is a
bottle neck to improve
coverage despite to be
inexpensive

2

Lack of provider preference
of Medical Abortion using
misoprostol

1

Financial constraints in
term of training TBA’s, cost
of drug

1

Lack of awareness/Clarity of 4
the guidelines/evidence.

4.

Number of
studies
identified similar
gap/barriers

2

3

Barriers or gaps related to
Health Service Delivery,
and availability and access
to essential medicine (10
Studies)

3
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implementation of critical interventions is crucial to
warrant that these interventions are prioritized and
that progress is measures [5].
6. Issues related to cost of medicine:
Only two studies (2/19)) have identified issues
related to the cost of medicine. A study conducted
in 37 developing countries focused on national level
findings revealed that Paying for medicine is a bottle
neck to improve coverage [5]. Similar findings were
shared by report on situational analysis conducted in
Ethiopia in 2012; and it was found that cost of
medicine was an issue [24]. Similar study further
added that there were financial constraints also in
term of training TBA’s [24].

Discussion
PPH is major contributor of maternal mortality in developing countries and accounts for more than 30% of maternal mortality in African and South Asian countries
[5]. Treating or preventing PPH with misoprostol can
avoid many complications and can reduce these preventable deaths. Large scale implementation of misoprostol
would contribute in achieving 2030- agenda of global
commitment that is to reduce Average global maternal
mortality ratio (MMR) of less than 70 maternal deaths
per 100,000 live births by 2030 along with Supplementary national target that by 2030, no country should have
an MMR greater than 140, a number twice the global
target [1, 3].
This review exhibited variations in misoprostol implementation from one geographic territory to another for
prevention of PPH and abortion related complications.
Literature regarding misoprostol implementation programs from developing countries illustrates that barriers
or gaps exist at all three levels of health system; community, facility and policy/ national level.
The most important barrier or gap for using Misoprostol to prevent PPH was inconsistencies in supplies/
fragmented supply chain and distribution of misoprostol
resulting into frequent stock out. A study conducted in
Kenya argued that institutional failure to allocate budget
to procure misoprostol was also resulted in delayed acquisition of this drug by 1 month [9]. A strategy to make
misoprostol widely available at community level specific
for prevention of post-partum hemorrhage also faced
political hurdles over its perceived misuse was the another possible reason for the inconsistencies in supply
chain [19].
Consistent with above discussed reasons, policy or system related causes are also linked with this frequently
highlighted supply and distribution issue. Review findings explored that some program officials and policy
makers were might be reluctant to promote a
community-based maternal health intervention due to
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existence of fear and apprehensions related to its use
and promotion [17–19]; they feel that home based distribution of misoprostol could increase the home based deliveries or it could be misused due to its abortion
inducing properties, and possibly will divert attention
away from implementing oxytocin– a superior drug. An
ambiguity, fear and apprehensions among key stake
holders on aforementioned distresses were identified as
potential cause for underlying barrier.
Among other barriers at policy level includes lack of
clear guidelines and unavailability of misoprostol labelled
for PPH specifically further increase the confusion.
There was also a fear of empowering women to participate in their health care and the controversy surrounding the use of misoprostol for abortion. In countries
where abortion is still restricted by law, there is a possibility of greater conflict if misoprostol is registered specifically for PAC or for advance community based
distribution, perhaps this would be abused for illegal
abortion as it happened in Latin America, that burst out
into intense political controversy. The findings from
multiple studies also witnessed perceived misused and
abortion inducing properties of misoprostol as the reason for non-registration of misoprostol specific for PPH
and for advance distribution of misoprostol in several
developing countries.
In addition to this; there were risk associated with limited community knowledge regarding dosage and timings and provider knowledge to differentiate between
PPH caused by atony or due to other causes such as
uterine rupture, vaginal lacerations and placental abnormalities; that have also increased the fear and confusion
at policy level to registered misoprostol in some of the
developing countries. One of the study has opposing
view in this regard and mentioned that not registering
mean that a marketing agreement is not formally in
place to permit its promotion and sale of drug for particular indication, it was further added that government
are not beholden to commercially registered and choose
to make a product available if it has public benefits [17].
Pursuing registration of misoprostol may in some cases
be useful to strategize for ensuring increase availability.
It has been established from the above discussion that
there was common root cause behind both the main issues that was fear and apprehensions among stake
holders (that includes policy makers, government officials and providers) that had a serious consequence in
supply and distribution of misoprostol and on registration status of misoprostol (as in Kenya). However, literature has identified fear and apprehension explicitly as a
separate barrier at provider level. The findings from
Ethiopia witnessed this fact that staff experience fear or
safety concerns includes giving misoprostol in a condition of undiagnosed twin (leading to fatal outcome),
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during labor (causes uterine rupture), and use of unsafe
abortion. In response to advance distribution; fear concerning intra-partum administration, undiagnosed multiple gestation, unsafe abortion, medication sharing and
possibility of its use after expiries were the major concern raised.
Beyond ensuring consistent supplies and uninterrupted distribution of misoprostol; another major contributor revealed from this review that impede proper
implementation of misoprostol was scarcity of staff or
inadequate staffing (SBA’s, TBA’s, CHW’s), staff requirement for the provision of PAC services were minimal.
This staffing shortage was also found at community
level, because access to SBA’s in remote areas was quite
difficult in developing countries. Misoprostol distribution through CHWs’ achieved high coverage [22] but it
is highly uncertain that to what extent does CHW’s
reach women resides in remote rural areas. Many conventional programs exclusively emphasized on increasing access to SBA’s with the use of TBA’s in the role to
advocate for skills care only. TBA’s were utilized in a role
that primarily urged women to obtain antenatal, obstetrics and postnatal care with little attention of enhancing
the skills set and knowledge base of TBA’s [30].
The programs that facilitates community based distribution of misoprostol represents such an opportunity to
think and implement task shifting strategies. This
highlighted the need for a comprehensive approach rather than focusing on single agenda of distribution
coverage. A success story of Northern Nigeria to improve supplies and access to misoprostol by enhancing
the community based distribution of misoprostol by
introducing the new cadre of community based drug
keepers and trained them; is feasible, safe and acceptable
intervention in settings where home based deliveries
were high and uterotonic coverage is limited. It not only
provides protection to women delivering at home but
also helped in overcoming structural and cultural barriers that limits women access to health facilities [28].
Further to above discussed issue, incomplete and inconsistent knowledge of provider about misoprostol including
appropriate dosage, timings, adverse effects, and required
monitoring. Possible reasons explored from studies include; training did not follow current guidelines, also
existing trainings are more inclined towards general management rather than current PAC related guidelines, Gaps
in pre-service medical and midwifery education program
curriculum, unavailability of refresher training to determine the ability to retained provided knowledge and learnt
skills. This inconsistency of provider knowledge and limited skilled set has implications for further training programs. Training additional number of CHWs/TBA’s as an
alternative strategy to reach women without access to
existing health services. Incorporating pre-service training
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using updated curriculum in light of current guidelines
would facilitate in the resolving above discussed staffing
and capacity issue.
Despite some concerns about stigma associated due to
its abortion inducing properties and perceived misuse in
above discussion among both audiences (providers and
end users), however review did not explore sufficient evidences related to acceptability barriers, lack of trust in
lower-cadre health workers, barriers due to ethnic and
cultural differences, disparities in service utilization between rural and urban.
Strengths of study

The main Strengths of this systematic review are the
context specific problem that have evaluative policy implications. Secondly systematic review made use of both
qualitative and quantitative set of data to better understand the barriers and their underlying reasons.
Study limitations

Data limitations, since it was a secondary analysis.
Conclusion and recommendations

Conclusion
Although literature demonstrates significant role Misoprostol use can play in prevention and management of
PPH and safe PAC services in context to developing
countries, yet the impact of this intervention on maternal indicators can be visible only once the intervention
is implemented and sustained. This requires bridging of
identified gaps and overcoming barriers by developing
supportive policies that actually overcome the fear and
apprehensions at policy, provider and community level,
training of health care providers including CHW’s and
TBA’s for its appropriate use and counsel them to overcome fears and apprehension/myths associated with its
use, correctly estimating the demand and designing a
formal plan to maintain adequate supplies and to prevent frequent stock out of misoprostol. It would also require task shifting strategies to overcome inadequate or
shortage of staffing.
These findings might be informative for the government officials, NGO’s, program personnel and policy
makers to implement efficiently, effectively and scale up
for sustainability to save women’s life.
Recommendations and policy implications

Findings of this systematic review have public health implications for programs in context to its availability,
feasibility, sustainability and scaling-up in better implementing misoprostol in developing countries. Below
mentioned are the some of the recommendation proposed in light identified findings
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Policy level:
 Countries must establish supportive policies for PPH
prevention, PAC services and advance distribution of
misoprostol in line with international standards that
reflect the latest research and the most recent WHO
recommendations.
 Registering misoprostol for PPH, PAC services and
for the management of incomplete abortion and
correctly approximating demand of misoprostol.
 Use of mass media campaigns, education materials
and community champions for extensive
dissemination of guidelines beyond distributing
them directly to users.
 Health monitoring and reporting system need to be
improved by tracking maternal health related
indicators, also PAC related service information
should be integrated into National HMIS and
national monitoring checklist
Facility/ provider Level
 Designing a formal plan to maintain adequate
supplies and to prevent frequent stock out of
misoprostol.
 Regular supervision and supportive mentoring to
ensure compliance to guidelines and protocols.
 TBA’s would be utilized in a role that primarily
urged women to obtain antenatal, obstetric and
post-natal care. This task shifting strategies will continue to encounter barriers related to limited or inadequate staffing.
 Provide training/ orient health care providers
including CHW’s and TBA’s on policies and
guidelines for its appropriate use and to make them
aware of existing policies and to overcome/clarify fear
and apprehensions/myths associated with its use.
Community Level:
 Strengthen awareness raising efforts with
communities and families to communicate the
potential benefits, correct usage of misoprostol,
counselling on danger signs, importance of
increasing facility births and clarification of myths
and misconceptions in order to effectively utilize it
and overcoming the community related concerns.
 Developing education and behavior change
communication (BCC) materials for all relevant
cadres and community members to ensure its
appropriate use, dosage, adverse effects and
reactions.
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